

DAFTAR PUSTAKA

1. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. *The lancet*. 2021;398(10308):1359–76.
2. Xiao S, Xie W, Zhang Y, Lei L, Pan Y. Changing epidemiology of cirrhosis from 2010 to 2019: results from the global burden disease study 2019. *Ann Med*. 2023;55(2).
3. Kementerian Kesehatan RI. Rencana aksi nasional pencegahan dan pengendalian hepatitis. 2020.
4. Lovena A, Miro S, Efrida E. Karakteristik pasien sirosis hepatis di RSUP Dr. M. djamil padang. *Jurnal kesehatan andalas*. 2017;6(1):5.
5. Premkumar M, Anand AC. Overview of complications in cirrhosis. *J Clin Exp Hepatol*. 2022;12(4):1150–74.
6. Garg SK, Goyal H, Obaitan I, Shah PA, Sarvepalli S, Jophlin LL, et al. Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the united states national readmissions database. *Ann transl med*. 2021;9(13):1052.
7. Asrani SK, Hall L, Hagan M, Sharma S, Yermaneni S, Trotter J, et al. Trends in chronic liver disease-related hospitalizations: a population-based study. *American journal of gastroenterology*. 2019;114(1):98–106.
8. Kaewput W, Thongprayoon C, Dumancas CY, Kanduri SR, Kovvuru K, Kaewput C, et al. In-hospital mortality of hepatorenal syndrome in the united states: Nationwide inpatient sample. *World J gastroenterol*. 2021;27(45):7831–43.
9. Singh J, Dahiya DS, Kichloo A, Singh G, Khoshbin K, Shaka H. Hepatorenal syndrome: A nationwide trend analysis from 2008 to 2018. *Ann med*. 2021;53(1):2018–24.
10. Kumar R, Kumar S, Prakash SS. Compensated liver cirrhosis: Natural course and disease-modifying strategies. *World J methodol*. 2023;13(4):179–93.
11. Wu HHL, Rakisheva A, Ponnusamy A, Chinnadurai R. Hepatocardiorenal syndrome in liver cirrhosis: recognition of a new entity? *World J gastroenterol*. 2024;30(2):128–36.

12. Bird TG, Ramachandran P, Thomson E. Decompensated liver cirrhosis. *Anaesthesia and intensive care medicine*. 2015;16(4):180–5.
13. Alsakarneh S, Jaber F, Mohammed W, Almeqdadi M, Al-Ani A, Kilani Y, et al. Applicability of child-turcotte-pugh score in anticipating post-ercp adverse events in patients with cirrhosis: a systematic review and meta-analysis. *J Clin gastroenterol*. 2024;58(6):554–63.
14. Mulya DP, Nurdjanah S, Ratnasari N. Original article correlation between child pugh score and Cystatin C. 2010.
15. Khemichian S, Francoz C, Durand F, Karvellas CJ, Nadim MK. Hepatorenal syndrome. *Crit care clin*. 2021;37(2):321–34.
16. Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK. Hepatorenal syndrome. *Clinical journal of the american society of nephrology*. 2019;14(5):774–81.
17. Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. *Therap adv gastroenterol*. 2022.
18. Nadim MK, Garcia G. Acute kidney injury in patients with cirrhosis. *New england journal of medicine*. 2023;388(8):733–45.
19. Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal syndrome: A review of pathophysiology and current treatment options. *Semin Intervent Radiol*. 2015;32(4):445–54.
20. Stulic M, Culafic D, Obrenovic R, Jankovic G, Alempijevic T, Lalosevic MS, et al. The clinical importance of Cystatin C and hepatic artery resistive index in liver cirrhosis. *Medicina (Lithuania)*. 2018;54(3):1–8.
21. Dahl H, Meyer K, Sandnes K, Welland NL, Arnesen I, Marti HP, et al. Cystatin C proteoforms in chronic kidney disease. *PLoS One*. 2023.
22. Murray MD, Trivax JE, Cullough PA. Serum Cystatin C, renal filtration function, and left ventricular remodeling. *Circ heart fail*. 2009;2(2):86–9.
23. Ahn HS, Kim YS, Kim SG, Kim HK, Min SK, Jeong SW, et al. Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels. *Hepatogastroenterology*. 2011.
24. Arnelis A, Yoga V, Zubir N, Miro S, Kurniawan A. Serum Cystatin C level in liver cirrhosis patients with meld-na. *The indonesian journal of gastroenterology, hepatology, and digestive endoscopy*. 2022;23(2):233–6.

25. Asal FE, Yousef M, Abdraboh HAA, Elsalam S, Abdelaziz S, Elbahnasawy M, et al. Role of serum Cystatin C as a diagnostic tool for renal function in cirrhotic patients. *Open Biomark J*. 2022;12(1).
26. Omar M, Abdel W, Abo G, Assem M, Elazab G. Evaluation of serum Cystatin C as a marker of early renal impairment in patients with liver cirrhosis. *Int J Hepatol*. 2015.
27. Ćulafić D, Štulić M, Obrenović R, Miletić D, Mijač D, Stojković M, et al. Role of Cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis. *World J gastroenterol*. 2014;20(21):6573–9.
28. Asrani SK, Hall L, Hagan M, Sharma S, Yeramaneni S, Trotter J, et al. Trends in chronic liver disease-related hospitalizations: a population-based study. *American journal of gastroenterology*. 2019;114(1):98–106.
29. Avazovna SS. Factors of development of hepatorenal syndrome in patients with liver cirrhosis of viral etiology. *Texas journal of medical science*. 2023;26:4–9.
30. Gloria K, Ewing N, Mackey L, Schlitt J, Marathe A, Abbas K. Sindrom hepatorenal. HHS public access. *Physiol Behav*. 2018;176(1):139–48.
31. Wang W, Xiao P, Xu H, Niu J, Gao Y. Growing burden of alcoholic liver disease in china: a review. *World J gastroenterol*. 2019;25(12):1445–56.
32. Chen X. Chinese clinical practice guideline for acute kidney injury. *National medical journal of china*. 2023;103(42):3332–66.
33. Meza V, Arnold J, Díaz LA, Ayala Valverde M, Idalsoaga F, Ayares G, et al. Alcohol consumption: medical implications, the liver and beyond. *Alcohol and alcoholism*. 2022;57(3):283–91.
34. Maucourt-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. *Int J Cancer*. 2018;142(12):2471–7.
35. Maharani B, Hendriani A, Iswari P. Liver cirrhosis: pathophysiology, diagnosis, and management. *Jurnal biologi tropis*. 2023;23(1):457–63.
36. Shah A, Amarapurkar D. Natural history of cirrhosis of liver after first decompensation: a prospective study in india. *J Clin Exp Hepatol*. 2018;8(1):50–7.

37. Adebayo D, Wong F. Pathophysiology of hepatorenal syndrome – acute kidney injury. *Clinical gastroenterology and hepatology*. 2023;21(10):1–10.
38. Francoz C, Durand F, Kahn J, Genyk Y, Nadim M. Hepatorenal syndrome. *Clinical journal of the american society of nephrology*. 2019;14(5):774–81.
39. Khemichian S, Francoz C, Durand F, Karvellas CJ, Nadim M. Hepatorenal syndrome. *Crit care clin*. 2021;37(2):321–34.
40. Kiani C, Zori A. Recent advances in pathophysiology, diagnosis and management of hepatorenal syndrome: A review. *World J Hepatol*. 2023;15(6):741–54.
41. Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. *J Hepatol*. 2018;69(2):406–60.
42. Addissouky T, Wang Y, Megahed F, Agroudy A, Sayed E, Torgoman E. Novel biomarkers assist in detection of liver fibrosis in HCV patients. *Egyptian liver journal*. 2021;11(1).
43. Tăluță C, Ștefănescu H, Crișan D. Seeing and sensing the hepatorenal syndrome (HRS): the growing role of ultrasound-based techniques as non-invasive tools for the diagnosis of HRS. *Diagnostics*. 2024;14(9).
44. Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. *World J Hepatol*. 2015;7(3):607–15.
45. Angeli P, Gines P, Wong F, Bernardi M, Boyer T, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the international club of ascites. *Gut*. 2015;64(4):531–7.
46. Angeli P, Garcia G, Nadim M, Parikh C. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the international club of ascites (ICA) consensus document. *J Hepatol*. 2019;71(4):811–22.
47. Attieh R, Wadei H. Acute kidney injury in liver cirrhosis. *Diagnostics*. 2023;13(14).
48. Patidar K, Cullaro G, Naved M, Kabir S, Grama A, Orman ES, et al. Prognostic significance of acute kidney injury stage 1b in hospitalized patients with cirrhosis: A US nationwide study. *Liver transplantation*. 2024;30(3):244–53.

49. Zulkifly S, Hasan I. Non-cirrhotic portal hypertension: An update of diagnosis and management. *The Indonesian journal of gastroenterology, hepatology, and digestive endoscopy*. 2023;24(2):143–53.
50. Amer M, Elsiey H. Ascites: causes, diagnosis, and treatment. *liver cirrhosis - update and current challenges*. 2017.
51. Sharawy E, Elkadeem M, Amer I. The predictors of hepatorenal syndrome development in HCV cirrhotic ascitic egyptian patients with spontaneous bacterial peritonitis. *Antiinflamm antiallergy agents med chem*. 2023;22(1):58–66.
52. Hidayat R, Raiz U, Ahmad R, Rahim M, Naseer A, Khan H. Frequency of hepatorenal syndrome in cirrhotic patients presenting with spontaneous bacterial peritonitis. *Medical forum monthly*. 2023;34(10):114–9.
53. Rose C, Amodio P, Bajaj J, Dhiman R, Montagnese S, Taylor S, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. *J Hepatol*. 2020;73(6):1526–47.
54. Fuhrmann V, Krowka M. Hepatopulmonary syndrome. *J Hepatol*. 2018;69(3):744–5.
55. Tapper B, Parikh D. Diagnosis and management of cirrhosis and its complications: A review. *JAMA*. 2023;329(18):1589–602.
56. Garg S, Goyal H, Obaitan I, Shah P, Sarvepalli S, Jophlin L, et al. Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the united states national readmissions database. *Ann transl med*. 2021;9(13):1052.
57. Utako P, Emyoo T, Anothaisintawee T, Yamashiki N, Thakkestian A, Sobhonslidsuk A. Clinical outcomes after liver transplantation for hepatorenal syndrome: A systematic review and meta analysis. *Biomed res int*. 2018;2018.
58. Pose E, Piano S, Juanola A, Ginès P. Hepatorenal syndrome in cirrhosis. *Gastroenterology*. 2024.
59. Sasso R, Yassine A, Deeb L. Predictors of development of hepatorenal syndrome in hospitalized cirrhotic patients with acute kidney injury. *J Clin Med*. 2021;10(23):1–13.

60. Subedi A, Suresh K, Sharma S, Sapkota B. A review of hepatorenal syndrome. *Cureus*. 2021.
61. Angeli P, Garcia G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the international club of ascites (ICA) consensus document. *J Hepatol*. 2019;71(4):811–22.
62. Allegretti A, Solà E, Ginès P. Clinical application of kidney biomarkers in cirrhosis. *American journal of kidney diseases*. 2020;76(5):710–9.
63. Gupta K, Bhurwal A, Law C, Ventre S, Minacapelli C, Kabaria S, et al. Acute kidney injury and hepatorenal syndrome in cirrhosis. *World J gastroenterol*. 2021;27(26):3984–4003.
64. Allegretti A, Parada X, Endres P, Zhao S, Krinsky S, Hillien S, et al. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A Prospective Study. *Clin transl gastroenterol*. 2021;12(5)
65. Çuhadar S. Serum Cystatin C as a biomarker. In: *biomarkers in kidney disease*. Dordrecht: springer netherlands; 2015. p. 1–17.
66. Asal F, Yousef M, Abdraboh H, Elsalam A, Abdelaziz S, Elbahnasawy M, et al. Role of serum Cystatin C as a diagnostic tool for renal function in cirrhotic patients. *Open Biomark J*. 2022;12(1):1–7.
67. Bhuyan B, Das J, Das M, Bhattacharya D, Nath C. Cystatin C as an early marker of renal dysfunction in patients with cirrhosis of liver: A cross-sectional study. *Journal of clinical and diagnostic research*. 2024;1–4.
68. Ahn H, Kim Y, Kim S, Kim H, Min S, Jeong S, et al. Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels. *Hepatogastroenterology*. 2012;59(116):1168–73.
69. Kim T, Lee H, Seo Y, Lee Y, Yim S, Lee Y, et al. Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum Cystatin C and urine N-acetyl- β -D-glucosaminidase. *Journal of gastroenterology and hepatology (Australia)*. 2019;34(1):234–40.
70. Saha R, Sharma S, Mondal A, Sati HC, Khan MA, Mahajan S, et al. Evaluation of serum kidney injury markers FABP1, NGAL, Cystatin C and the

- inflammatory cytokine IL-18 in the detection of acute on chronic liver failure (ACLF) associated acute kidney injury (AKI). 2022.
71. Yaswir R, Maiyesi A. Pemeriksaan laboratorium Cystatin C untuk uji fungsi ginjal. *jurnal kesehatan andalas*. 2012;1(1).
72. Kim TH, Lee HA, Seo YS, Lee YR, Yim SY, Lee YS, et al. Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetyl- β -D-glucosaminidase. *J Gastroenterol Hepatol*. 2019 Jan 21;34(1):234–40.
73. Nagy E, Abdelfattah AH, Sayed-Ahmed N, Ahmed S. Cystatin C as a predictor of renal recovery and in hospital mortality in patients with acute kidney injury and liver cirrhosis. *BMC Nephrol*. 2025;26(1).
74. El-Makarem MA, Mousa MM, Ayaad LA, Keryakos HK. Comparative study of various glomerular filtration rate estimating equations in Egyptian patients with hepatitis C virus-related liver cirrhosis: a single-center observational study. *Egyptian Liver Journal*. 2021;11(1).
75. Padia G, Mahajan B, Kumar A, Sonika U, Dahale AS, Sachdeva S, et al. Cystatin C and interleukin-6 for prognosticating patients with acute decompensation of cirrhosis. *JGH Open*. 2021;5(4):459–64.
76. Alhaddad O, Elsabaawy M, Abedelhai A, Badra G, Elfayoumy M. Impact of age on frailty in liver cirrhosis: a prospective cohort study. *Clin Exp Med*. 2025;25(1):1–8.
77. Zeleke TK, Bazezew ZA, Abebe RB. The Burden of Inappropriate Prescriptions and Predictors for Hospitalized Patients with Liver Cirrhosis in Ethiopia. *Hepat Med*. 2023;Vol. 15 :129–40.
78. Duo H, You J, Du S, Yu M, Wu S, Yue P, et al. Liver cirrhosis in 2021: Global Burden of Disease study. *PLoS One*. 2025; Vol. 20 :1–14.
79. Rubin JB, Sundaram V, Lai JC. Gender Differences Among Patients Hospitalized With Cirrhosis in the United States. *J Clin Gastroenterol*. 2020 Jan;54(1):83–9.
80. Makuza JD, Jeong D, Wong S, Binka M, Adu PA, Velásquez García HA, et al. Association of hepatitis B virus treatment with all-cause and liver-related

- mortality among individuals with HBV and cirrhosis: a population-based cohort study. *The Lancet Regional Health - Americas*. 2024;36:1–13.
81. Tham EK, Tan DJ, Danpanichkul P, Ng CH, Syn N, Koh B, et al. The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021. *Liver International*. 2025;45(3).
82. Suksamai A, Chaiprasert A, Chirapongsathorn S. Serum cystatin C as a predictor of 90-day mortality among patients admitted with complications of cirrhosis. *JGH Open*. 2021;5(5):607–13.
83. Lim J, Kim JH, Lee A, Han JW, Lee SK, Yang H, et al. Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis. *Gut Liver*. 2025;19(3):427–37.
84. Hong C, Zhu Q, Li Y, Tang S, Lin S, Yang Y, et al. Acute kidney injury defined by cystatin C may be superior for predicting the outcomes of liver cirrhosis with acute gastrointestinal bleeding. *Ren Fail*. 2022;44(1):398–406.
85. Siregar GA, Gurning M. Renal dysfunction in liver cirrhosis and its correlation with Child-Pugh score and MELD score. *IOP Conf Ser Earth Environ Sci*. 2018;125(1):3–9.
86. Ahmed S, Kayesh AM, Wahiduzzaman, Mahmud M, Kibria G, Ahmed F, et al. Correlation of Serum Creatinine with Child-Pugh Score among Patients with Decompensated Cirrhosis of Liver. *The Planet*. 2023;6(02):31–9.
87. Kumar S, Shah S, Singh B, Pradhan A. Comparison Between Creatinine-Modified Pugh Score and Child-Pugh Score for Prognostication in Decompensated Cirrhosis. *Cureus*. 2024;16(6).
88. Bibi A, Ahmed S, Khan M, Raza A, Hussain M, Iqbal F, et al. Role of serum Cystatin C in assessment of renal dysfunction in cirrhotic patients. *Cureus*. 2025;17(3):e39125.
89. Lei L, Wang J, Chen Y, Zhang H, Liu X, Zhou Y, et al. Diagnostic value of serum cystatin C for early renal dysfunction in patients with liver cirrhosis. *BMC Gastroenterology*. 2020;20:62.
90. Shazly MA, El-Kady HM, Abdelrahman AM, Abdelaziz AA, Hassan MM. Serum cystatin C versus serum creatinine as a marker of renal impairment in patients with liver cirrhosis. *Egypt J Intern Med*. 2018;30(2):67–73.

91. Al-Mamun A, Rahman MM, Islam MS, Hossain MM, Karim MR. Evaluation of serum cystatin C as an early marker of renal dysfunction in patients with liver cirrhosis. *Mymensingh Med J.* 2019;28(4):819–826.
92. Zhao C, Wang Y, Zhang H, Li X, Liu J, Chen Y, et al. Serum cystatin C is superior to creatinine for early detection of renal dysfunction in patients with liver cirrhosis. *BMC Gastroenterology.* 2021;21:148

